News & Media Center
MTF Biologics to Highlight Wound Care Innovations at Symposium on Advanced Wound Care Spring | Wound Healing Society Meeting
May conference to feature new data demonstrating the efficacy of MTF Biologics’ tissue grafts in treating diabetic foot ulcers and complex wounds
Edison, NJ (May 7, 2019) – MTF Biologics, a leading nonprofit tissue bank dedicated to saving and healing lives, will be featuring its line of placental and dermal wound care innovations at this year’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Health Society Meeting. The event, which serves as a forum to connect wound care teams with the foremost experts to improve patient outcomes, will be held at the Henry B. Gonzalez Convention Center in San Antonio, Texas, May 7 – 11, 2019.
“Chronic wounds, including diabetic foot ulcers, continue to pose significant heath challenges to hundreds of thousands of Americans each year,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “We’re committed to research and development of both dermal and placental solutions that offer new options for healing these types of wounds, while honoring the gift of donated tissue.”
The nonprofit organization will showcase its line of innovations including:
- AmnioBand® Viable, an aseptically processed viable human amnion membrane for use as an acute or chronic wound covering; and
- AlloPatch® Pliable Allograft Dermal Matrix, a minimally-processed dermal human allograft derived from the deeper reticular layer of dermal tissue.
“Our expansive portfolio of dermal and placental innovations demonstrates our dedication to enhancing clinical outcomes,” said Marc Long, PhD, Vice President of Research and Development at MTF Biologics. “We’re thrilled to be at this year’s spring event and look forward to showcasing the many ways we save and heal lives, as well as how our offerings outperform current treatment options.”
In addition to highlighting its wound care innovations, MTF Biologics will host an Industry Supported Symposium titled, “Looking Beneath the Surface: New Level 1 Evidence and Comparative Data for DFUs & Complex Wound Case Studies.” Four of the leading names in wound care research, Dennis Orgill, MD, PhD; Lawrence DiDomenico, DPM; Paul Glat, MD, FACS; and Michael Desvigne, MD; will present on recently-published Level 1 clinical outcomes for an aseptically processed, dehydrated human amnion and chorion tissue. The complimentary lunch symposium will be held in Room 213 on Wednesday, May 8 from 12 – 1:30 p.m.
Additionally, clinical and scientific poster presentations will be held on Thursday, May 9 from 7:15-8:45 p.m. These include:
- Components in Cryopreserved Viable Amnion Support the Shift of Chronic to Acute Inflammation in Elderly Patients with Chronic Lower Extremity Wounds – Gidwani, Regulski, Meradian, Wu, Chnari, Dasgupta; Abstract: CS-026
- Aseptically Processed Meshed Human Reticular Dermal Allografts Provide the Scaffold to Support Human Fibroblast Growth and Granulation Activities Which Can Facilitate Surgical Wound Closure – Gidwani, Phipps, Chnari, Dasgupta; Abstract: LR-021
Dr. Michael Desvigne, industry expert and plastic surgeon, will discuss and demonstrate MTF Biologics’ wound care offerings at the Tissue Experience Station at booth #337 while the exhibit is open.
For more information on MTF Biologics, visit www.mtfbiologics.org.
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 132,000 donors, distributed more than 8.6 million grafts for transplantation, and provided more than $50M in research grants. Through its IIAM subsidiary, it has placed more than 58,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 11.3 million donor referrals. For more information, visit www.mtfbiologics.org.
Media Contact: Christian Lail, 615-610-0307, christian.lail@dvlseigenthaler.com
Latest Press
MTF Biologics to Highlight Wound Care Innovations at Symposium on Advanced Wound Care Spring | Wound Healing Society Meeting
May conference to feature new data demonstrating the efficacy of MTF Biologics’ tissue grafts in treating diabetic foot ulcers and complex wounds
Edison, NJ (May 7, 2019) – MTF Biologics, a leading nonprofit tissue bank dedicated to saving and healing lives, will be featuring its line of placental and dermal wound care innovations at this year’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Health Society Meeting. The event, which serves as a forum to connect wound care teams with the foremost experts to improve patient outcomes, will be held at the Henry B. Gonzalez Convention Center in San Antonio, Texas, May 7 – 11, 2019.
“Chronic wounds, including diabetic foot ulcers, continue to pose significant heath challenges to hundreds of thousands of Americans each year,” said Kim Rounds, Vice President of Wound Care at MTF Biologics. “We’re committed to research and development of both dermal and placental solutions that offer new options for healing these types of wounds, while honoring the gift of donated tissue.”
The nonprofit organization will showcase its line of innovations including:
- AmnioBand® Viable, an aseptically processed viable human amnion membrane for use as an acute or chronic wound covering; and
- AlloPatch® Pliable Allograft Dermal Matrix, a minimally-processed dermal human allograft derived from the deeper reticular layer of dermal tissue.
“Our expansive portfolio of dermal and placental innovations demonstrates our dedication to enhancing clinical outcomes,” said Marc Long, PhD, Vice President of Research and Development at MTF Biologics. “We’re thrilled to be at this year’s spring event and look forward to showcasing the many ways we save and heal lives, as well as how our offerings outperform current treatment options.”
In addition to highlighting its wound care innovations, MTF Biologics will host an Industry Supported Symposium titled, “Looking Beneath the Surface: New Level 1 Evidence and Comparative Data for DFUs & Complex Wound Case Studies.” Four of the leading names in wound care research, Dennis Orgill, MD, PhD; Lawrence DiDomenico, DPM; Paul Glat, MD, FACS; and Michael Desvigne, MD; will present on recently-published Level 1 clinical outcomes for an aseptically processed, dehydrated human amnion and chorion tissue. The complimentary lunch symposium will be held in Room 213 on Wednesday, May 8 from 12 – 1:30 p.m.
Additionally, clinical and scientific poster presentations will be held on Thursday, May 9 from 7:15-8:45 p.m. These include:
- Components in Cryopreserved Viable Amnion Support the Shift of Chronic to Acute Inflammation in Elderly Patients with Chronic Lower Extremity Wounds – Gidwani, Regulski, Meradian, Wu, Chnari, Dasgupta; Abstract: CS-026
- Aseptically Processed Meshed Human Reticular Dermal Allografts Provide the Scaffold to Support Human Fibroblast Growth and Granulation Activities Which Can Facilitate Surgical Wound Closure – Gidwani, Phipps, Chnari, Dasgupta; Abstract: LR-021
Dr. Michael Desvigne, industry expert and plastic surgeon, will discuss and demonstrate MTF Biologics’ wound care offerings at the Tissue Experience Station at booth #337 while the exhibit is open.
For more information on MTF Biologics, visit www.mtfbiologics.org.
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 132,000 donors, distributed more than 8.6 million grafts for transplantation, and provided more than $50M in research grants. Through its IIAM subsidiary, it has placed more than 58,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 11.3 million donor referrals. For more information, visit www.mtfbiologics.org.
Media Contact: Christian Lail, 615-610-0307, christian.lail@dvlseigenthaler.com
MTF Biologics is a registered trademark of the Musculoskeletal Transplant Foundation.